NEW YORK (October 10, 2005) — McDermott Will & Emery client DaVita Inc. (NYSE: DVA), has completed its purchase of the U.S. renal care business of Sweden's Gambro Healthcare. To complete its acquisition of Gambro, the Federal Trade Commission (FTC) and state regulators required DaVita to divest approximately 70 freestanding renal dialysis centers, a majority of which were purchased by Renal Advantage Inc. (RAI).
In addition to advising on various aspects of the purchase of Gambro, McDermott Will & Emery represented DaVita in this sale to RAI and all regulatory antitrust work surrounding the transactions, including approval form the FTC and the California and Michigan Attorney General's offices. As a result of the acquisition of Gambro and the sale of these divestitures DaVita now serves approximately 94,000 patients at over 1,200 clinics in more than 41 states and the District of Columbia.
McDermott Will & Emery served as M&A counsel on the transaction and JPMorgan Securities Inc. acted as financial advisor. The McDermott team was led by partners Jeff Stone in Chicago, and included Gary Gertler and Meir Lewittes, who advised on M&A issues. Ray Jacobsen, Joel Grosberg and Greg Heltzer of the Firm's Washington, D.C. office advised on regulatory issues and Dan Zucker in Chicago addressed tax issues. Ellie Hourizadeh advised on health law issues; Joshua Buchman and Mike Kendall advised on litigation issues.
DaVita is a leading provider of dialysis services for patients suffering from chronic kidney failure. Gambro, a Swedish corporation controlled by the Wallenberg family, is a global medical technology and health care company organized into three medical technology and health care services: Gambro Healthcare, Gambro Renal Products and Gambro BCT. Gambro Renal Products develops, manufactures and supplies hemodialysis, peritoneal dialysis and acute dialysis equipment.